Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study

Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study

Abstract Background Anemia has been a known prognostic factor in metastatic hormone-sensitive prostate cancer (mHSPC). We therefore examined the effect of anemia on the efficacy of upfront abiraterone acetate (ABI) in patients with mHSPC. Methods We retrospectively evaluated 66 mHSPC patients with h...

Full description

Bibliographic Details
Main Authors: Teppei Okamoto, Daisuke Noro, Shingo Hatakeyama, Shintaro Narita, Koji Mitsuzuka, Toshihiko Sakurai, Sadafumi Kawamura, Senji Hoshi, Jiro Shimoda, Toshikazu Tanaka, Toshiaki Kawaguchi, Shigeto Ishidoya, Akihiro Ito, Norihiko Tsuchiya, Tomonori Habuchi, Chikara Ohyama
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Cancer
Subjects:
Prostate cancer
Hormone-sensitive
Abiraterone acetate
Upfront therapy
Prognosis
Anemia
Online Access:https://doi.org/10.1186/s12885-021-08206-8

Internet

https://doi.org/10.1186/s12885-021-08206-8

Similar Items